KI’s new President: “We need to work closer together”

A closer link between research and education and a stronger “we-feeling” are aims that Annika Östman Wernerson sets out to achieve as the new President of Karolinska Institutet. She will not give up her research entirely though. “I think it’s crucial to maintain a close presence in the business,” she says.

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising discovery about the function of the immune system.

The government proposes fines for pharmaceutical companies that fail to notify drug shortages in time

According to a compilation from the Swedish Medicines Agency, the number of residually notified medicines increased by 54 % in Sweden last year compared to the previous year. In a bill presented by the government a number of proposals are put forward to counteract the problem.

The new Astra Zeneca CEO: “An incredibly exciting phase”

Almost 27 years have passed since Per Alfredsson from Södertälje stepped into Astra Zeneca as a newly hired engineer. After countless different roles, including heading the production of the company’s Covid vaccine, he is now advancing to the absolute top.

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.

Swedish breakthrough in Alzheimer’s: “We can finally present great data”

Treatments for Alzheimer’s disease are currently among the hottest topics in drug development. Two Swedish research companies with high ambitions and successes in the field participated in Bioscience 2022 conference at Life City in Hagastaden, Stockholm.

Göran Stiernstedt: “We are the world’s worst at continuity”

Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt does not mind his language when describing the shortcomings of today’s healthcare system. “It makes me extremely frustrated,” he says.

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

”Kriminella handlar allt mer med falska läkemedel”

Under coronapandemin har försäljningen av förfalskade läkemedel skiftat om till läkemedel och produkter för covid-19.

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Krönika: Collaboration across borders

Engage with your CMO early

Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of Development at Spago Nanomedical says.

They’re all doing it – buying drug research

December 12 the time has come for this year's annual partnering meeting Pharma Outsourcing in Stockholm. In Sweden this is a growing business, with Recipharm as the biggest CRMO of the country.

The best wealth is Health

We are living in a world where wealth more and more is measured in being able to do the things you like and enjoy in life. As the wealth increases in terms of economic strength, the expectation of a long and healthy life increases and with that a demand of enjoy life.

Opinion: Where do all the cool Swedish life science companies go?

It’s puzzling why Swedish life science companies hardly get a mention alongside Spotify, Skype, Klarna, King, iZettle, and other cool, innovative and successful ‘startups’ founded in Sweden.

Swedish life science in political focus

It feels like 2017 will be a good year for Swedish life science, says Anders Blanck, CEO at LIF.

Ny chef på Sectra

Mats Franzén är ny finanschef på medtechbolaget.

Uppåt för Sectra

Ökar resultatet men vill få ut mer från affärsområdet Secure Communications.

Framåt för Ellen

Når 230 nya apotek.

Fördubblar närvaron i UK

Enzymaticas partner tecknar avtal med brittisk apotekskedja.

Sectra köper finskt

Förvärvar det finska konsultbolaget EXP Analytics.

Sectra ökar försäljningen

Har ökat orderingången det senaste året men ser en minskad marknad i Storbritannien framöver.

Enzymatica ökar försäljningen

Det Lundabaserade bioteknikföretaget Enzymatica redovisar en nettoomsättning på 1,27 miljoner kr under årets andra kvartal. Att jämföra med 0,5 miljoner kr för motsvarande period föregående år. Resultet efter skatt minskade till –7,50 miljoner kr (–3,54 miljoner kr). Det framgår av bolagets delårsrapport.